Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma

NCT05755087 is registered in ClinicalTrials.gov with Lapo Alinari as lead sponsor.

NCT NCT05755087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05755087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of Tegavivint in Patients With Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma
Lead sponsor
Lapo Alinari
Phase
Phase 1
Overall status
Recruiting
Start date
March 6, 2023
Completion date
March 5, 2028
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma activated b-cell type, recurrent diffuse large b-cell lymphoma germinal center b-cell type, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, refractory diffuse large b-cell lymphoma activated b-cell type, refractory diffuse large b-cell lymphoma germinal center b-cell type, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory high grade b-cell lymphoma with myc, bcl2, and bcl6 rearrangements, transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma